Delivery Order SPE2DB20D2014-SPE2DB24FA77D
Award Date 1/10/24
Potential Completion Date 1/11/24
Potential Value $2.8K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply the DLA with HUMIRA(CF) PEN 40 MG/0.4 MLS. This order, valued at $75,138.37, has an ultimate completion date of April 22, 2024. Amerisourcebergen also holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through December 31, 2025, to provide a comprehensive range of pharmaceutical products and medical...
- The U.S. Defense Logistics Agency (DLA) awarded a $2,770.74 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS medication. This order falls under Amerisourcebergen's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,199.08 Firm Fixed Price delivery order to Amerisourcebergen Drug Corp. The order, which has an ultimate completion date of October 15, 2024, is for 4566086883 - HUMIRA PEN 40 MG/0.8 MLS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $10,770.89 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical product. The $4,455.88 order has a completion date of February 28, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract valued at $13,901.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide range of...
- The U.S. Defense Logistics Agency (DLA) awarded a $5,344.82 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division to supply 4,565,058,929 units of the pharmaceutical product HUMIRA(CF) PEN 40 MG/0.4 MLS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 held by Amerisourcebergen with DLA Troop Support Medical, which enables the agency to efficiently procure a comprehensive range of pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,794.38 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. The contract has an ultimate completion date of August 15, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these critical medical supplies through an existing Indefinite Delivery Contract (IDC) valued up to $999,999,999 with the DLA Troop Support Medical. This IDC...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4,563,731,826 units of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical product. The delivery order has a potential value of $5,537.88 and a completion date of February 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,694.32 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office Division for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB24FA77DDelivery Order
The U.S. Defense Logistics Agency (DLA) awarded a $2,770.74 firm fixed-price delivery order to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The order is for 4,563,298,226 units of the drug HUMIRA(CF) PEN 40 MG/0.4 MLS and has a completion date of January 11, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This order was issued without a set-aside designation.
Generated 7/26/24, 11:18 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 1/10/24 |